Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21

Journal of Clinical Oncology

Volumn 29, Issue 16, 2011, Pages

  Masago, Katsuhiro ^a   Miura, Masako ^a   Toyama, Yoshiro ^a   Togashi, Yosuke ^a   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; ERLOTINIB; THYROGLOBULIN;

AGED; ANAPLASTIC THYROID CARCINOMA; ARM EDEMA; ARTICLE; ASPIRATION BIOPSY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER SIZE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FACE EDEMA; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; MEDIASTINUM LYMPH NODE; PERIODIC ACID SCHIFF STAIN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNET RING CARCINOMA; SWELLING; THYROID CARCINOMA; TRANSBRONCHIAL BIOPSY; TREATMENT RESPONSE; WILD TYPE;

ADENOCARCINOMA, PAPILLARY; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SIGNET RING CELL; DNA MUTATIONAL ANALYSIS; EPIDERMAL GROWTH FACTOR; EXONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; POLYMERASE CHAIN REACTION; QUINAZOLINES; THYROID NEOPLASMS;

EID: 79957939913     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.0216     Document Type: Article

References (16)

1. Nagai Y, Miyazawa H, Huqun, et al: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65:7276-7282, 2005 (Pubitemid 41161259)
2. Sutani A, Nagai Y, Udagawa K, et al: Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 95:1483-1489, 2006 (Pubitemid 44863350)
3. Tanaka T, Nagai Y, Miyazawa H, et al: Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci 98:246-252, 2007 (Pubitemid 44941878)
4. Haugen BR: Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 16:34-41, 1999
5. Sherman SI: Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 94:1493-1499, 2009
6. Ye L, Santarpia L, Gagel RF: The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev 31:578-599, 2010
7. Cohen EE, Rosen LS, Vokes EE, et al: Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 26:4708-4713, 2008
8. Sherman SI, Wirth LJ, Droz JP, et al: Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42, 2008 (Pubitemid 351931094)
9. Gupta-Abramson V, Troxel AB, Nellore A, et al: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719, 2008
10. Kloos RT, Ringel MD, Knopp MV, et al: Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684, 2009
11. Cohen EE, Needles BM, Cullen KJ, et al: Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 26:322s, 2008 (suppl; abstr 6025)
12. Wells SA Jr, Gosnell JE, Gagel RF, et al: Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28:767-772, 2010
13. Schiff BA, McMurphy AB, Jasser SA, et al: Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 10:8594-8602, 2004 (Pubitemid 40053427)
14. Pennell NA, Daniels GH, Haddad RI, et al: A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18:317-323, 2008 (Pubitemid 351415790)
15. Fury MG, Solit DB, Su YB, et al: A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 59:467-475, 2007 (Pubitemid 46122325)
16. Masago K, Asato R, Fujita S, et al: Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. Int J Cancer 124:2744-2749, 2009